RxDoctor Payments Data

Gregory Jackson

Optometrist · Mobile, ALNPI 1114922036

Payments from drug & device makers

$1,387in general payments, 2019–2025

Across 58 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$355
  • Bausch & Lomb Americas Inc.$174
  • Coopervision Inc.$161
  • Optos, Inc.$134
  • AbbVie$118
  • Tarsus Pharmaceuticals, Inc.$105
  • plus $341 from 10 others

What the payments were for

  • Food & beverage$1,23589%
  • Education$181%
  • Entertainment$13410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,387 in reported general payments places this provider in the 60th percentile of 749 optometrist providers in Alabama.

See all optometrist providers in Alabama

Medicare billing

Part B allowed, 2024
$105,716
Medicare patients
735
Services billed
1,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine32$32,760
LumiganBimatoprost93$25,203
Prednisolone Acetate186$6,150
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol62$5,829
Latanoprost634$5,006
Travoprost49$4,917
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha182$2,519
Timolol Maleate206$1,944
Brimonidine Tartrate126$1,400
Ofloxacin79$946
Tobramycin-DexamethasoneTobramycin/Dexamethasone15$631
Cephalexin57$619
Famciclovir15$545
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat28$396
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim44$366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$118$57,962125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 749 optometrist providers in Alabama.

Other optometrist in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →